Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION A CRL citing manufacturing, not efficacy put 505(b)(2) literature-to-product bridge table in front of RWE evidence-strategy director in a company with a CMC site change mid-review. This Pharma & Life Sciences / Clinical and Evidence Strategy close is to drop a secondary from 505(b)(2) literature-to-product bridge table, and the live options are Proceed under protocol, Pause the pathway, Escalate safety review.

DECISION RWE evidence-strategy director in a company with a CMC site change mid-review must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after a CRL citing manufacturing, not efficacy.

HYPOTHESES TO TEST 1. The population in 505(b)(2) literature-to-product bridge table is the one a CRL citing manufacturing, not efficacy named, so Proceed under protocol follows for this Clinical and Evidence Strategy file. 2. The population in 505(b)(2) literature-to-product bridge table is adjacent only to a CRL citing manufacturing, not efficacy; Pause the pathway is the honest Pharma & Life Sciences call. 3. A company with a CMC site change mid-review already contained a CRL citing manufacturing, not efficacy before 505(b)(2) literature-to-product bridge table arrived; no new Clinical and Evidence Strategy path. 4. Provenance on 505(b)(2) literature-to-product bridge table after a CRL citing manufacturing, not efficacy is broken; do not pick Proceed under protocol or Pause the pathway yet.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 3. Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim RWE evidence-strategy director would keep. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read 505(b)(2) literature-to-product bridge table against a CRL citing manufacturing, not efficacy and write the one fact that would move to drop a secondary for RWE evidence-strategy director.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (505(b)(2) literature-to-product bridge table after a CRL citing manufacturing, not efficacy). Lead with the Pharma & Life Sciences option 505(b)(2) literature-to-product bridge table can support after a CRL citing manufacturing, not efficacy, then the two facts that force it, then the Monday action for RWE evidence-strategy director in a company with a CMC site change mid-review.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in 505(b)(2) literature-to-product bridge table, then the action for RWE evidence-strategy director - Hypothesis scorecard against 505(b)(2) literature-to-product bridge table: supported / rejected / untestable - Owner and next date for RWE evidence-strategy director in a company with a CMC site change mid-review - What changes to drop a secondary if a CRL citing manufacturing, not efficacy is later withdrawn